Method for detecting impurities in intermediates of oligonucleotide drugs targeting PCSK9 gene
Impurities separation and identification in oligonucleotide drugs in the prior art are solved by using a stationary phase octadecylsilane-bonded silica gel chromatography column and a specific mobile phase high performance liquid chromatography combined with mass spectrometry technology in oligonucleotide drugs. The problem of this paper achieves efficient isolation and identification of intermediates targeted PCSK9 gene drug, and improves the accuracy of quality control and purity analysis.
Patent Information
- Application Number
- CN202411190256.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-28
AI Technical Summary
In the identification and purification of oligonucleotide drugs and intermediates, there are many problems with the combination of liquid chromatography and mass spectrometry, and it is impossible to effectively isolate and identify the shortening of the sense strand and antisense strand in targeted PCSK9 gene drugs. Sequence impurities, thio incomplete sequence impurities and growth sequence impurities, and the selection of mobile phase affects the compatibility of the mass spectrometer, resulting in inaccurate identification of impurities.
Using a stationary phase octadecylsilane bonded silica gel chromatography column, the mobile phase is 1,1,1,3,3-hexafluoro-2-propanol and n-hexylamine and a mixture of methanol and acetonitrile to pass high efficiency Liquid chromatography combined with mass spectrometry technology separates and identifys impurities in oligonucleotide drugs, ensures good volatility of the mobile phase, avoids blockage and damage of the mass spectrometer, and improves the impurity removal and reproducibility of impurity separation.
It realizes efficient separation and identification of sense strand and antisense strand intermediates in oligonucleotide drugs, and can simultaneously identify shortened sequences, thio incomplete sequences and growth sequence impurities, improving the quality control and purity analysis of intermediates Accuracy and credibility.
Smart Images

Figure CN118707003B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug detection, and in particular relates to a method for detecting intermediate impurities of an oligonucleotide drug targeting a PCSK9 gene. Background Art
[0002] In recent years, therapeutic oligonucleotides have attracted increasing market attention as a drug model that may treat a variety of diseases. Approved treatments were initially limited to the treatment of rare diseases. However, after the PCSK9 gene-targeting Inksilan sodium injection was approved for cholesterol-lowering treatment of patients with atherosclerotic cardiovascular disease, the research and development and production of this type of oligonucleotide drugs have received more and more attention from related companies.
[0003] Currently, oligonucleotide drugs are mainly synthesized using solid-phase phosphoamido chemistry, a process that includes iterative coupling, capping, oxidation, and deprotection steps to extend the nucleotide sequence. However, since the reaction efficiency of each step cannot reach 100%, intermediates and finished products contain more sequence-related impurities. The presence of sequence-related impurities makes oligonucleotide drugs have certain safety risks during use. In order to improve the safety of use, it is necessary to identify and separate the impurities generated during the synthesis process.
[0004] The introduction of mass spectrometry and liquid chromatography in the quality research of oligonucleotide drugs has provided a technical basis for the rapid clinical application of therapeutic oligonucleotide drugs. In theory, separation of impurities by liquid chromatography and analysis of the corresponding impurities by mass spectrometry can not only achieve quality control of the finished product, but also quickly guide process optimization and save cost investment. However, in the actual production process, it was found that the combination of liquid chromatography and mass spectrometry still has many problems and limitations in the identification and purification of oligonucleotide drugs and their intermediates.
[0005] For example:
[0006] Quality Aspects of Oligonucleotide Drug Development: Srecificationsfor Active Pharmaceutical Ingredients[J]. Drug Information Journal, 2012, 46(5):611-626 proposed that mass spectrometry and liquid chromatography can be used for identification and purity detection of oligonucleotides, but in liquid chromatography, only retention time can be used as a reliable method for identification. However, due to the large number of oligonucleotide impurities, the separation condition is poor, and sequence identification based only on a single liquid chromatography or mass spectrometry method is not powerful enough.
[0007] Assay, Purity, and Impurity Profile of PhosphorothioateOligonucleotide Therapeutics by Ion Pair–HPLC–MS[J].Nucleic acidtherapeutics, 2022, 32(3):206-220. A liquid-mass spectrometry method was established to analyze the related substances of different phosphorothioate oligonucleotide drugs. However, in the method provided, the incomplete phosphorothioate sequence impurity (P=O)1 was not separated, and the content could only be detected by extracting ion flow through EIC, and no method for identifying oligonucleotides was proposed.
[0008] CN118050441A discloses a method for separating and identifying oligonucleotide N and its N-1 impurity. The method uses an anion exchange chromatography column to separate and identify oligonucleotide N and its N-1 impurity, but it mainly relies on retention time for identification, and the mobile phase used is a non-volatile salt solution, which has poor compatibility with mass spectrometry and cannot be used in conjunction with mass spectrometry for impurity identification.
[0009] Therefore, there is an urgent need to develop oligonucleotide drug identification and purity analysis methods that are reproducible and effectively compatible with mass spectrometers. Summary of the invention
[0010] In view of the above-mentioned defects and shortcomings in the prior art, the present invention provides a method for detecting impurities in an intermediate of an oligonucleotide drug targeting the PCSK9 gene.
[0011] The method provided by the present invention can simultaneously identify and separate shortened sequence impurities, incomplete thiolation sequence impurities and extended sequence impurities of the sense chain and the antisense chain in the intermediate, and has a good impurity removal effect. Moreover, the method has good reproducibility between batches and can be used for quality control of the intermediate.
[0012] The inventors of the present invention have found that when using liquid chromatography and mass spectrometry to separate impurities (also known as "impurity removal") and identify the purity of oligonucleotide drugs or their intermediates, the selection of liquid chromatography mobile phase is very important. On the one hand, different mobile phases have different effects on the separation of oligonucleotides, especially the selection of ions in the mobile phase and the adjustment of the composition and concentration of reagents, which can affect the separation of impurities and main components; on the other hand, liquid chromatography and mass spectrometry technology requires that the mobile phase selected for chromatography has good volatility. If a mobile phase additive with poor volatility is used, the residual salt after volatilization will cause clogging and damage to the mass spectrometer.
[0013] Based on this, the present invention provides a method for detecting impurities in an intermediate of an oligonucleotide drug targeting the PCSK9 gene, which comprises using high performance liquid chromatography to separate and detect impurities in a test solution containing the oligonucleotide drug intermediate, wherein the conditions of the liquid chromatography include:
[0014] The chromatographic column used is selected from a chromatographic column whose stationary phase uses octadecylsilane bonded silica gel as a filler; and
[0015] The mobile phase A is selected from an aqueous solution of 1,1,1,3,3,3-hexafluoro-2-propanol and n-hexylamine;
[0016] Mobile phase B is selected from a mixed solution of methanol and acetonitrile;
[0017] The oligonucleotide drug comprises a sense strand and an antisense strand, the nucleotide sequence of the sense strand is shown in SEQ ID NO:7, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO:8;
[0018] The impurities include one or more of the sequence impurities of the nucleotide sequence such as SEQ ID NO: 1-6.
[0019] In the present invention, "impurities" mainly refer to nucleotide sequence impurities (also referred to as "sequence impurities"), that is, other oligonucleotide sequences that are different from the target oligonucleotide sequence (including differences in nucleotide sequence length, nucleotide type and arrangement, and different modifications on the nucleotide sequence).
[0020] The method provided by the present invention can detect any one or more impurities selected from the following:
[0021] Shortened sequence impurities, extended sequence impurities and incomplete thiolation impurities in oligonucleotide drug intermediates;
[0022] Wherein, the shortened sequence impurities include oligonucleotide sequences that lack at least one base in the sequence of the sense strand and / or the antisense strand;
[0023] The growing sequence impurities include an oligonucleotide sequence that adds at least one base to the sequence of the sense strand and / or the antisense strand;
[0024] The thiolated incomplete sequence impurities include oligonucleotide sequences in which at least one target base in the sequence of the sense strand and / or the antisense strand is not thiolated.
[0025] In the present invention, the shortened sequence impurities have no particular restrictions on the specific position of the nucleotide deletion, as long as at least one nucleotide is deleted in the oligonucleotide sequence (regardless of the sense chain or the antisense chain) compared with the target oligonucleotide sequence, it is the shortened sequence impurity. In the present invention, the extended sequence impurities have no particular restrictions on the position of the nucleotide addition, as long as at least one nucleotide is added in the oligonucleotide sequence (regardless of the sense chain or the antisense chain) compared with the target oligonucleotide sequence, it is the extended sequence impurity. In the present invention, the thio-incomplete sequence impurities have no particular restrictions on the position where the target base is not thio-modified, as long as the nucleotide sites that should have thio-modification in the oligonucleotide sequence (regardless of the sense chain or the antisense chain) are not modified compared with the target oligonucleotide sequence, or other types of modifications are performed, they can be regarded as the thio-incomplete sequence impurities.
[0026] For example, the shortened sequence impurity can be an oligonucleotide sequence in which any 1-20 nucleotides are missing relative to the target sense strand (SEQ ID NO: 7). For example, the amount of nucleotide missing can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or can be a range consisting of any two of the above values, or any intermediate value in the range.
[0027] For example, the shortened sequence impurity can be an oligonucleotide sequence in which any 1-22 nucleotides are missing relative to the target antisense strand (SEQ ID NO: 8). For example, the amount of nucleotide missing can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or can be a range consisting of any two of the above values, or any intermediate value in the range.
[0028] For example, the growing sequence impurity can be an oligonucleotide sequence obtained by adding at least one nucleotide at any position in the sequence of the sense strand (SEQ ID NO: 7) or the antisense strand (SEQ ID NO: 8). For example, the number of added nucleotides can be 1-100, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a range consisting of any two of the above values, or any intermediate value in the range.
[0029] Preferably, the thiolated incomplete sequence impurities include an oligonucleotide sequence in which at least one of the two target bases (i.e., the first G and the second A in the 5'→3' sequence of the sense strand) is not thiolated. For example, the first G in the 5'→3' sequence of the sense strand is not thiolated, the second A is not thiolated, or both the first G and the second A are not thiolated.
[0030] Preferably, the thiolated incomplete sequence impurities include an oligonucleotide sequence in which at least one of the four target bases (i.e., the second A, the third A, the twenty-second A, and the twenty-third A of the antisense strand 5'→3') is not thiolated. For example, any one, any two, or any three of the second A, the third A, the twenty-second A, and the twenty-third A of the antisense strand 5'→3' may not be thiolated, or none of the above four sites may be thiolated.
[0031] It should be noted that in the above description of incomplete thiolation impurities, "not thiolated" means that the site in the target sequence that should be thiolated is not thiolated, which may include that the site is not modified at all, or that the site is modified by any other type of modification other than thiolation.
[0032] According to some preferred embodiments of the present invention, the impurities include at least one sequence shown in SEQ ID NO: 1-6. It should be noted that SEQ ID NO: 1-6 only lists several impurity sequences that are very close to the target sense chain sequence or the target antisense chain sequence structure and are difficult to separate from the target sequence (for example, these impurity sequences cannot be separated from the target sequence using methods in the prior art). Those skilled in the art should be able to understand that in the case where the method provided by the present invention can remove the impurity sequence of the nucleotide sequence such as any one of SEQ ID NO: 1-6, the method should also be able to remove impurity sequences with other structures, and can obtain a removal effect at least equivalent to these impurity sequences.
[0033] The oligonucleotide drug intermediates and impurities involved in the method provided by the present invention at least include the oligonucleotide sequences listed in the following oligonucleotide sequence structure information table. In the following table:
[0034] The position marked with “_” represents a deletion of 1 base;
[0035] Described by the following chemical symbols:
[0036] C = cytosine, U = uracil, A = adenine, G = guanine; m = 2'-O-methyl modified sugar, f = 2'-F modified sugar; EVP = vinyl phosphate bond, s = phosphorothioate internucleoside bond;
[0037] G5 = [[(1R, 2R, 3R, 4R)-1-[[28-[[2-(Acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-13,13-bis[[3-[[3-[[5-[[2-(Acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-11,18,24-trioxo-15-oxa-12,19,23-triazaoctacosan-1-yl]oxy]-2-methoxy-5-β-D-ribofuranosyl] hydrogen phosphate.
[0038]
[0039] According to a preferred embodiment of the present invention, the impurity is a mixture of sequence impurities such as the nucleotide sequence shown in SEQ ID NO: 1-6.
[0040] According to a preferred embodiment of the present invention, in mobile phase A, the concentration of 1,1,1,3,3,3-hexafluoro-2-propanol is 100-300 mmol / L; the concentration of n-hexylamine is 10-30 mmol / L.
[0041] For example, in mobile phase A, the concentration of 1,1,1,3,3,3-hexafluoro-2-propanol can be 100mmol / L, 120mmol / L, 140mmol / L, 160mmol / L, 180mmol / L, 200mmol / L, 220mmol / L, 240mmol / L, 260mmol / L, 280mmol / L, 300mmol / L, or it can be a range consisting of any two of the above values, or any intermediate value in the range.
[0042] For example, in mobile phase A, the concentration of n-hexylamine can be 10mmol / L, 12mmol / L, 14mmol / L, 16mmol / L, 18mmol / L, 20mmol / L, 22mmol / L, 24mmol / L, 26mmol / L, 28mmol / L, 30mmol / L, or it can be a range consisting of any two of the above values, or any intermediate value in the range.
[0043] Preferably, in mobile phase A, the concentration of 1,1,1,3,3,3-hexafluoro-2-propanol is 200 mmol / L.
[0044] Preferably, in mobile phase A, the concentration of n-hexylamine is 25 mmol / L.
[0045] According to a preferred embodiment of the present invention, in the mobile phase B, the volume ratio of methanol to acetonitrile is 1:1.
[0046] According to a preferred embodiment of the present invention, the particle size of the filler of the chromatographic column is 1.7-2.7 μm.
[0047] For example, the particle size of the filler of the chromatographic column can be 1.7μm, 1.8μm, 1.9μm, 2μm, 2.1μm, 2.2μm, 2.3μm, 2.4μm, 2.5μm, 2.6μm, 2.7μm, or a range consisting of any two of the above values, or any intermediate value in the range.
[0048] Preferably, the particle size of the filler of the chromatographic column is 1.7 μm.
[0049] According to a preferred embodiment of the present invention, the specification of the chromatographic column is 2.1-4.6 mm×50-150 mm.
[0050] For example, the specification of the chromatographic column may be any one of 4.6 mm×100 mm, 4.6 mm×250 mm, and 2.1 mm×150 mm.
[0051] Preferably, the size of the chromatographic column is 2.1 mm×150 mm.
[0052] In some preferred embodiments of the present invention, in the liquid chromatography conditions, the elution gradient is:
[0053]
[0054] That is, the elution gradient of the liquid chromatography is:
[0055] From 0 to 20 min, the volume of mobile phase B changed from 25% to 50%;
[0056] At 20-22 min, the volume of mobile phase B was changed from 50% to 60%;
[0057] At 22-22.1 min, the volume of mobile phase B was changed from 60% to 25%;
[0058] From 22.1 to 27 min, the volume of mobile phase B was maintained at 25%.
[0059] According to a preferred embodiment of the present invention, the concentration of the oligonucleotide drug in the test solution is 0.1-1 mg / mL. (That is, the concentration of the sense strand is 0.1-1 mg / mL, or the concentration of the antisense strand is 0.1-1 mg / mL)
[0060] For example, the concentration of the oligonucleotide drug can be 0.1 mg / mL, 0.2 mg / mL, 0.3 mg / mL, 0.4 mg / mL, 0.5 mg / mL, 0.55 mg / mL, 0.6 mg / mL, 0.65 mg / mL, 0.7 mg / mL, 0.75 mg / mL, 0.8 mg / mL, 0.85 mg / mL, 0.9 mg / mL, 0.95 mg / mL, 1 mg / mL, or a range consisting of any two of the above values, or any intermediate value in the range.
[0061] Preferably, in the test solution, the concentration of the oligonucleotide drug intermediate is 0.5-0.75 mg / mL.
[0062] According to a preferred embodiment of the present invention, the liquid chromatography conditions further include: a column temperature of 70°C.
[0063] According to a preferred embodiment of the present invention, the liquid chromatography conditions further include: a flow rate of 0.27-0.33 mL / min. For example, it may be 0.27 mL / min, 0.28 mL / min, 0.29 mL / min, 0.3 mL / min, 0.31 mL / min, 0.32 mL / min, 0.33 mL / min, or a range consisting of any two of the above values, or any intermediate value in the range.
[0064] Preferably, the flow rate is 0.3 mL / min.
[0065] According to a preferred embodiment of the present invention, the liquid chromatography conditions further include: the detection wavelength is 258-262 nm, for example, it can be 258 nm, 259 nm, 260 nm, 261 nm, 262 nm, or it can be a range consisting of any two of the above values, or any intermediate value in the range.
[0066] Preferably, the detection wavelength is 260 nm.
[0067] According to a preferred embodiment of the present invention, the liquid chromatography conditions further include: the injection volume is 1-5 μL, for example, 1 μL, 2 μL, 3 μL, 4 μL, 5 μL, or a range consisting of any two of the above values, or any intermediate value in the range.
[0068] Preferably, the injection volume is 2 μL.
[0069] In some more preferred embodiments, the retention times of the oligonucleotide pharmaceutical intermediates and impurities include:
[0070]
[0071] Among them, the relative deviation RD of retention time is less than 1%.
[0072] According to a preferred embodiment of the present invention, the method further comprises the step of preparing a test solution, which comprises contacting the oligonucleotide drug with a diluent.
[0073] In the present invention, the diluent may be any reagent that can be used to dilute / dissolve an oligonucleotide drug or an intermediate thereof in liquid chromatography.
[0074] Preferably, the diluent is water and / or methanol. That is, the diluent can be water (such as deionized water, ultrapure water, etc.), methanol, or an aqueous solution of methanol.
[0075] More preferably, the content of methanol in the aqueous solution of methanol is 5-15% by volume, for example, 5% by volume, 6% by volume, 7% by volume, 8% by volume, 9% by volume, 10% by volume, 11% by volume, 12% by volume, 13% by volume, 14% by volume, 15% by volume, or a range consisting of any two of the above values, or any intermediate value in the range.
[0076] According to some preferred embodiments of the present invention, the diluent is water.
[0077] According to some preferred embodiments of the present invention, the method further comprises the step of using mass spectrometry to detect the purity of the product obtained by liquid chromatography.
[0078] Preferably, the conditions for mass spectrometry include: the ion source is an electrospray ion source.
[0079] Preferably, the mass spectrometry conditions include: the acquisition polarity is a negative polarity mode.
[0080] Preferably, the mass spectrometry conditions include: the acquisition range is m / z=600-3000.
[0081] Preferably, the conditions for mass spectrometry include: a capillary voltage of 3.0 KV.
[0082] Preferably, the mass spectrometry conditions include: a drying gas temperature of 350°C.
[0083] The beneficial effects achieved by the present invention include at least:
[0084] The present invention provides a method for simultaneously identifying and separating a target oligonucleotide intermediate sense chain and sense chain impurity 1 (shortened sequence 5'n-1), impurity 2 (thio-incomplete sequence impurity), impurity 3 (extending sequence impurity 5'n+Gms), as well as a target antisense chain and antisense chain impurity 4 (shortened sequence impurity 5'n-1), impurity 5 (thio-incomplete sequence impurity), impurity 6 (extending sequence impurity 5'n+Afs).
[0085] Among them, the peak-to-valley ratios of impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolation sequence impurity), and impurity 3 (extended sequence impurity 5'n+Gms) in the sense chain with the main peak are all greater than 1.00, and the peak shapes are obvious, which can achieve the separation of the main peak of the sense chain and the three impurities.
[0086] Except for impurity 5 (incomplete thiolation sequence impurity), the peak-to-valley ratios of impurity 4 (shortened sequence 5'n-1) and impurity 6 (extended sequence impurity 5'n+Afs) with the main peak in the antisense chain are all greater than 1.00, and the peak shapes are obvious, which can achieve the separation of the main peak of the antisense chain and the two impurities.
[0087] Under the above separation effect, liquid chromatography coupled with a high-resolution mass spectrometer was used to identify and detect the intermediates of the sense chain and antisense chain. The mass spectrum data of each peak in the fingerprint spectrum of the sense chain and antisense chain were analyzed, the molecular weight of the corresponding impurity peak was identified, and its base deletion was inferred. Based on the uniqueness of the sequence, the identification of the target oligonucleotide sequence was effectively achieved through the difference in molecular weight.
[0088] In addition, in the method provided by the present invention, by selecting the chromatographic column and mobile phase selected for liquid chromatography, the product obtained by liquid chromatography separation can be further identified by mass spectrometry, thereby further improving the purity identification precision and accuracy of the separated product, and the detection result is more reliable. BRIEF DESCRIPTION OF THE DRAWINGS
[0089] Figure 1 Chromatogram of the mixed impurity reference solution;
[0090] Figure 2 Chromatogram for identification of the sense strand intermediate solution;
[0091] Figure 3 Chromatogram for identification of antisense strand intermediate solution;
[0092] Figure 4 The chromatogram is a chromatogram of the test product measured using the method of Comparative Example 1;
[0093] Figure 5 The chromatogram is obtained by using the method of Comparative Example 2 to measure the test product;
[0094] Figure 6 The chromatogram is a chromatogram of the mixed impurity reference substance determined using the method of Example 2;
[0095] Figure 7 The chromatogram is a chromatogram of the mixed impurity reference substance assayed using method 1 of Example 3;
[0096] Figure 8 The chromatogram is a chromatogram of the mixed impurity reference substance determined using method 2 of Example 3;
[0097] Fig. 9 The chromatogram is a chromatogram of the mixed impurity reference substance determined using method 1 of Example 4;
[0098] Fig.10 The chromatogram is a chromatogram of the mixed impurity reference substance determined using method 2 of Example 4;
[0099] Fig.11 The chromatogram is obtained by measuring the mixed impurity reference substance using method 3 of Example 4. DETAILED DESCRIPTION
[0100] The present invention is further described below in conjunction with examples. However, the present invention is not limited to the following examples. The implementation conditions used in the examples can be further adjusted according to the different requirements of specific use, and the implementation conditions not specified are conventional conditions in the industry. In the specific examples of the present invention, the raw materials used can be obtained commercially. Unless otherwise specified, the percentages in the context are weight percentages, and all temperatures are given in degrees Celsius. The technical features involved in each embodiment of the present invention can be combined with each other as long as they do not conflict with each other.
[0101] Example 1: Specificity test
[0102] The oligonucleotides used in this example (including the sense strand, the antisense strand and related impurity sequences) were further refined after synthesis, which significantly reduced the impurity levels therein.
[0103] 1-1. Solution preparation:
[0104] Diluent: ultrapure water;
[0105] Mobile phase A: an aqueous solution of 1,1,1,3,3,3-hexafluoro-2-propanol and n-hexylamine, wherein the concentration of 1,1,1,3,3,3-hexafluoro-2-propanol is 200 mmol / L; the concentration of n-hexylamine is 25 mmol / L;
[0106] Mobile phase B: methanol: acetonitrile (V / V) = 50:50;
[0107] Blank solvent: water;
[0108] Prepare the test solution as follows:
[0109] Test solution 1: Take 15 μL of the intermediate positive chain (SEQ ID NO: 7) solution with a concentration of 50 mg / mL and place it in a 2 mL EP tube, add 985 μL of water, mix well, and prepare a 0.75 mg / mL positive chain solution as test solution 1;
[0110] Test solution 2: Take 15 μL of the intermediate antisense strand (SEQ ID NO: 8) solution with a concentration of 50 mg / mL and place it in a 2 mL EP tube, add 985 μL of water, mix well, and prepare a 0.75 mg / mL antisense strand solution as test solution 2;
[0111] Impurity stock solution: Prepare the positive chain impurity 1 (shortened sequence 5'n-1, SEQ ID NO: 1) with a concentration of 0.5 mg / mL as the impurity stock solution 1.
[0112] The same method was used to prepare the impurity stock solutions of impurities 2-6 (SEQ ID NO: 2-6) at the same concentration.
[0113] Impurity localization solution: Take 300 μL of the positive chain impurity 1 stock solution (shortened sequence 5'n-1, SEQID NO: 1) with a concentration of 0.5 mg / mL, and add 1700 μL of ultrapure water to prepare a 0.075 mg / mL impurity localization solution.
[0114] The same method was used to prepare impurity localization solutions of impurities 2-6 (SEQ ID NO: 2-6) at the same concentration.
[0115] Mixed impurity reference solution: Take 300 μL of impurity stock solutions 1-6 respectively, take 30 μL of test solution 1 and test solution 2 respectively, mix the solutions together in a 2 mL EP tube, then add 1070 μL of water and mix well to obtain a mixed impurity reference solution containing 0.075 mg of the mixed sequence per 1 mL.
[0116] 1-2. Test conditions:
[0117] Instrument: High performance liquid chromatography;
[0118] Chromatographic column: Octadecylsilane bonded silica gel is used as filler, and the chromatographic column specifications are selected as: WatersACQUITY TM UPLC Oligonucleotide BEH C18, 2.1 mm × 150 mm, 1.7 μm column;
[0119] Mobile Phase:
[0120] Mobile phase A: an aqueous solution of 1,1,1,3,3,3-hexafluoro-2-propanol and n-hexylamine, wherein the concentration of 1,1,1,3,3,3-hexafluoro-2-propanol is 200 mmol / L; the concentration of n-hexylamine is 25 mmol / L;
[0121] Mobile phase B: methanol: acetonitrile (V / V) = 1:1;
[0122] Column temperature: 70°C;
[0123] Injection volume: 2 μL;
[0124] Detector: UV detector;
[0125] Detection wavelength: 260nm;
[0126] Flow rate: 0.3 mL / min;
[0127] Elution method: gradient elution, see Table 1 for details;
[0128] Table 1 Elution gradient
[0129]
[0130] Elution time: 27min.
[0131] The liquid chromatography product was subjected to mass spectrometry detection. Specific mass spectrometry parameters are shown in Table 2.
[0132] Table 2 Mass spectrometry parameters
[0133]
[0134] 1-3. Experimental steps and conclusions:
[0135] Accurately measure 2 μL of the blank solution, test solution, each impurity location solution and mixed impurity reference solution prepared according to the method in 1-1, and inject them into the high performance liquid chromatograph respectively, and record the chromatogram and results. The results are shown in Table 3-7 below.
[0136] Table 3 Test results of test solution
[0137]
[0138] Table 4 Results of positive chain positioning solution test
[0139]
[0140] Table 5 Antisense strand positioning solution test results
[0141]
[0142] Note: If the relative deviation of retention time RD is less than 1%, it is considered to be the characteristic peak of the same substance. The calculation method is as follows:
[0143] , where A is the retention time of the positioning solution and B is the retention time in the system suitability test results.
[0144]
[0145]
[0146] in conclusion:
[0147] The above samples were separated and tested by high performance liquid chromatography, and the test results show that:
[0148] In Table 3, a blank solvent was used for the specificity positioning test. No extra characteristic peaks were generated in the chromatogram of the blank solvent, indicating that the blank solvent did not interfere with the determination of the main peak and various impurities; and from the spectrum of the test solution, it can be seen that the retention times of the characteristic peaks of the sense chain and the antisense chain are 9.665min and 11.550min, respectively.
[0149] The area normalization method was used to report the percentage of the characteristic peak area of the sense chain and the antisense chain as purity. The purity of the sense chain was 94.0% and the purity of the antisense chain was 88.0%. The calculation formula is as follows:
[0150] Sense chain characteristic peak area percentage / purity%
[0151] Antisense strand characteristic peak area percentage / purity%
[0152] Tables 4 and 5 show the results of the detection of each known impurity using the impurity location solution, combined with the mixed impurity reference solution ( Figure 1 ) It can be seen that the retention times of the sense chain impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolation sequence impurity), and impurity 3 (extended sequence impurity 5'n+Gm) are 9.402min, 9.506min, and 9.973min, respectively. The retention times of the antisense chain impurity 4 (shortened sequence impurity 5'n-1), impurity 5 (incomplete thiolation sequence impurity), and impurity 6 (extended sequence impurity 5'n+Af) are 9.865min, 11.550min, and 11.940min, respectively.
[0153] System suitability test using mixed impurity reference solution Figure 1 The results showed that the peak-to-valley ratios of impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolation sequence impurity), and impurity 3 (extended sequence impurity 5'n+Gm) in the sense chain with the main peak were all greater than 1.00, and the peak shapes were obvious, which could achieve the separation of the main peak of the sense chain and the three impurities.
[0154] Except for impurity 5 (incomplete thiolation sequence impurity) in the antisense chain, the peak-to-valley ratios of impurity 4 (shortened sequence 5'n-1) and impurity 6 (extended sequence impurity 5'n+Gm) with the main peak were all greater than 1.00, and the peak shapes were obvious, which could achieve the separation of the main peak of the antisense chain and the two impurities.
[0155] Table 6 and Table 7, Figure 2 and Figure 3In order to use liquid chromatography coupled to a high-resolution mass spectrometer to identify the detection results of the sense chain and antisense chain intermediates, the mass spectrum data of each peak in the fingerprint spectrum of the sense chain and antisense chain were analyzed to identify the base deletion of the corresponding retention time peak. Since the oligonucleotide sample sequence is unique and the base category is fixed, the target oligonucleotide sequence is effectively identified through the difference in molecular weight.
[0156] Example 2: Selection of chromatographic column
[0157] On the basis of Example 1, the filler type of the chromatographic column was changed, and other chromatographic conditions remained unchanged, and 12 known impurities in the oligonucleotide drug intermediate were detected.
[0158] 2 μL of the mixed impurity reference solution prepared in Example 1 was accurately measured and injected into high performance liquid chromatographs using different chromatographic columns. The results are shown in Table 8.
[0159] Table 8
[0160]
[0161] in conclusion:
[0162] 1. When using Waters ACQUITY UPLC Oligonucleotide BEH C18 (2.1mm×150mm, 1.7μm) chromatographic column, except for the antisense chain impurity 5 (incomplete thiolation sequence impurity), the main peak and the other 5 impurities in the obtained spectrum all have peak responses, sharp peaks, and good detection sensitivity.
[0163] Among them, impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolated sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), and impurity 6 (extended sequence impurity 5'n+Af) can all be separated from the main peak, with sharp and obvious peaks, no other interfering peaks, a stable baseline, and good detection sensitivity, which can realize the separation and detection of known impurities in intermediates.
[0164] 2. When using Waters ACQUITY UPLC Oligonucleotide BEH C8 (2.1mm×100mm, 1.7μm) chromatographic column, the characteristic peaks of antisense chain impurity 4 (shortened sequence 5'n-1) and sense chain impurity 3 (extended sequence impurity 5'n+Gm) overlap and are not separated, and each peak becomes wider and the peak shape becomes worse, resulting in a decrease in detection sensitivity and the purpose of purity detection cannot be achieved. See the spectrum for details. Figure 6 .
[0165] summary:
[0166] From the above comparison, it can be seen that in the present invention, when the chromatographic column with octadecylsilane bonded silica gel as the filler is used, the impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolated sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), impurity 6 (extended sequence impurity 5'n+Af) and the main peak can be better separated.
[0167] On the contrary, when using chromatographic columns with other fillers (for example, the C8 chromatographic column in Table 8) for separation, the antisense chain impurity 4 (shortened sequence 5'n-1) and the antisense chain characteristic peak overlap and are not separated, and each peak becomes wider and the peak shape becomes worse, making it impossible to achieve the purpose of separation and purity detection.
[0168] Example 3: Selection of mobile phase solvent
[0169] On the basis of Example 1, the type of mobile phase B was changed, and other chromatographic conditions remained unchanged, and 6 known impurities (SEQ ID NOs: 1-6) in the oligonucleotide drug intermediate were detected.
[0170] Other test conditions were the same as those in Example 1. 2 μL of the mixed impurity reference solution prepared in Example 1 was accurately measured and injected into the high performance liquid chromatograph. The results are shown in Table 9.
[0171] Table 9
[0172]
[0173] in conclusion:
[0174] The separation and detection of the six impurities of oligonucleotide drugs by high performance liquid chromatography using the two different solvents mentioned above revealed that:
[0175] 1. Using the mobile phase B of Example 1, except for the antisense chain impurity 5 (the impurity with an incomplete thiolation sequence), the main peak and the five impurities in the obtained spectrum all have peak responses, the peak shape is sharp, and the detection sensitivity is good.
[0176] Among them, impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolated sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), and impurity 6 (extended sequence impurity 5'n+Af) can all be separated from the main peak, with sharp and obvious peaks, no other interfering peaks, a stable baseline, and good detection sensitivity, which can realize the separation and detection of known impurities in intermediates.
[0177] 2. In the spectra obtained using other mobile phases, the main peak and the characteristic peaks of the five impurities overlap. Example 3-Method 1 (see Figure 7 ) The peaks are obviously broadened, the peaks overlap, and the peak response decreases; Example 3-Method 2 (see Figure 8 ) Each peak is split, and it is impossible to separate and detect the main peak and five impurities.
[0178] summary:
[0179] From the above comparison, it can be seen that when the mobile phase B of the present invention is used (for example, the mixed solution of methanol: acetonitrile (V / V) = 1:1 selected in Example 1), except for the antisense chain impurity 5 (the incomplete thiolated sequence impurity), the main peak and the five impurities in the obtained spectrum all have peak responses, the peak shape is sharp, and the detection sensitivity is good.
[0180] Impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolated sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), and impurity 6 (extended sequence impurity 5'n+Af) can all be separated from the main peak, with sharp and obvious peaks, no other interfering peaks, a stable baseline, and good detection sensitivity, which can realize the separation and detection of known impurities in intermediates.
[0181] On the contrary, when other mobile phases (for example, methanol or acetonitrile aqueous solution selected in Example 3) are used for separation, each peak is split and some peaks overlap, and the purpose of separation cannot be achieved.
[0182] Example 4: Selection of mobile phase ion pair reagent type
[0183] On the basis of Example 1, the ion pair reagent in mobile phase A was changed, and other chromatographic conditions remained unchanged, and the oligonucleotide drug intermediate was detected.
[0184] Other test conditions were the same as those in Example 1. 2 μL of the mixed impurity reference solution prepared in Example 1 was accurately measured and injected into the high performance liquid chromatograph. The results are shown in Table 10.
[0185] Table 10
[0186]
[0187] in conclusion:
[0188] The oligonucleotide drug intermediates were analyzed by HPLC using the mobile phase A of the three different ion pair reagents, and it was found that:
[0189] 1. Except for the antisense chain impurity 5 (sulfo-incomplete sequence impurity), the main peak and five impurities in the obtained spectrum all have peak responses, with sharp peaks and good detection sensitivity.
[0190] Among them, impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolated sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), and impurity 6 (extended sequence impurity 5'n+Af) can all be separated from the main peak, with sharp and obvious peaks, no other interfering peaks, a stable baseline, and good detection sensitivity, which can realize the separation and detection of known impurities in intermediates.
[0191] 2. When triethylamine is used as the mobile phase ion pair reagent in method 1 of Example 4, the antisense chain impurity 4 (shortened sequence 5'n-1), antisense chain impurity 6 (extended sequence impurity 5'n+Af) and antisense chain characteristic peaks overlap and are not separated. Sense chain impurity 1 (shortened sequence 5'n-1) and sense chain are not separated, as shown in the spectrum. Fig. 9 .
[0192] 3. When dibutylamine was used as the mobile phase ion pair reagent in method 2 of Example 4, the antisense chain was split into two peaks, and the antisense chain impurity 4 (shortened sequence 5'n-1), the antisense chain impurity 6 (extended sequence impurity 5'n+Af) and the antisense chain characteristic peaks overlapped, and separation could not be achieved. See the spectrum. Fig.10 .
[0193] 4. When the mobile phase ion pair reagents of method 3 of Example 4 are 1,1,1,3,3,3-hexafluoro-2-methyl-2-propanol and n-hexylamine, the antisense chain is split into two peaks, and the antisense chain impurity 6 (growing sequence impurity 5'n+Af) and the antisense chain characteristic peak overlap, and separation cannot be achieved. See the spectrum. Fig.11 .
[0194] summary:
[0195] The experimental results of the above-mentioned different ion pair reagent mobile phases prove that the use of the mobile phase of Example 1 (for example, Example 1) can achieve that, except for the antisense chain impurity 5 (the incomplete thiolated sequence impurity), the main peak and the five impurities in the obtained spectrum all have peak responses, the peak shape is sharp, and the detection sensitivity is good.
[0196] On the contrary, when other types of mobile phases (for example, methods 1 to 3 in Example 4) were used for separation, their characteristic peaks overlapped and separation could not be achieved; under some conditions, the main peak showed obvious splitting, and the split peaks were identified as single components. This is because the oligonucleotide product is a mixture of a series of different configurations, which exhibited different chromatographic behaviors under an inappropriate mobile phase, making it impossible to separate the five impurities, and the peak-to-valley ratio did not meet the requirements; and the main peak of the antisense chain was obviously split into two peaks, which was not conducive to the separation and study of impurities, and did not show a better separation effect than Example 1.
[0197] Example 5: Selection of mobile phase ion pair reagent concentration
[0198] On the basis of Example 1, the concentration of the ion pair reagent was changed, and other chromatographic conditions remained unchanged, and the oligonucleotide drug intermediate was detected.
[0199] Other test conditions were the same as those in Example 1. 2 μL of the mixed impurity reference solution prepared in Example 1 was accurately measured and injected into the HPLC. The results are shown in Table 11.
[0200] Table 11
[0201]
[0202] in conclusion:
[0203] The oligonucleotide drugs were analyzed by HPLC using the mobile phase ion pair reagents of the three different concentrations, and it was found that:
[0204] 1. Except for the antisense chain impurity 5 (sulfo-incomplete sequence impurity), the main peak and five impurities in the obtained spectrum all have peak responses, with sharp peaks and good detection sensitivity.
[0205] Among them, impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolated sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), and impurity 6 (extended sequence impurity 5'n+Af) can all be separated from the main peak, with sharp and obvious peaks, no other interfering peaks, a stable baseline, and good detection sensitivity, which can realize the separation and detection of known impurities in intermediates.
[0206] 2. Using the ion pair reagent concentrations of methods 1 to 4 of Example 5, the peaks of impurity 3 (extended sequence impurity 5'n+Gm) and impurity 4 (shortened sequence impurity 5'n-1) partially overlap, and the separation of adjacent impurities of the antisense chain is poor. When a higher concentration of 1,1,1,3,3,3-hexafluoro-2-propanol (400 mmol / L) is used, the baseline noise increases significantly.
[0207] 3. Using the ion pair reagent concentration of method 5 in Example 5, the peaks of impurity 3 (impurity 5'n+Gm of increasing sequence) and impurity 4 (impurity 5'n-1 of shortening sequence) partially overlap and cannot be separated.
[0208] 4. Using the ion pair reagent concentration of method 6 of Example 5, it was found that n-hexylamine could not be completely dissolved after multiple ultrasounds during the preparation of the mobile phase, and the chromatographic baseline fluctuated greatly after injection, and no chromatographic peaks of impurities and main components were observed.
[0209] summary:
[0210] By using the preferred mobile phase ion pair reagent concentration of the present invention, that is, 1,1,1,3,3,3-hexafluoro-2-propanol concentration of 200mmol / L and n-hexylamine concentration of 25mmol / L, impurity 1 (shortened sequence 5'n-1), impurity 2 (thio-incomplete sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), impurity 6 (extended sequence impurity 5'n+Af) and the main peak can be separated, the baseline is stable, the detection sensitivity is good, and the separation and detection of known impurities in the intermediate can be realized.
[0211] On the contrary, when other proportions of mobile phase ion pair reagent concentrations (for example, the mobile phase ion pair reagent concentrations of methods 1 to 5 in Example 5) are used for separation, the characteristic peaks overlap and separation cannot be achieved; and when the concentration of n-hexylamine is further increased, the chromatographic baseline fluctuates greatly and the system baseline is difficult to balance.
[0212] Example 6: Selection of column temperature
[0213] On the basis of Example 1, the column temperature was changed, and other chromatographic conditions remained unchanged, and the oligonucleotide drug intermediate was detected.
[0214] Among them, the column temperature setting and the test results are shown in Table 12 below:
[0215] Table 12
[0216]
[0217] in conclusion:
[0218] The oligonucleotide drug intermediates were analyzed by HPLC at the above three different column temperatures and found that:
[0219] 1. Using the column temperature of Example 1, except for the antisense chain impurity 5 (the impurity of the incomplete thiolated sequence), the main peak and the five impurities in the obtained spectrum all have peak responses, the peak shape is sharp and the peak is smooth, and the detection sensitivity is good.
[0220] Among them, impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolated sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), and impurity 6 (extended sequence impurity 5'n+Af) can all be separated from the main peak, with sharp and obvious peaks, no other interfering peaks, a stable baseline, and good detection sensitivity, which can realize the separation and detection of known impurities in intermediates.
[0221] 2. When the column temperature of method 1 and method 2 of Example 6 is used, the characteristic peaks of impurity 3 (extended sequence impurity 5'n+Gm) and impurity 4 (shortened sequence impurity 5'n-1) overlap and cannot be separated; and the main peak is broadened, and as the temperature decreases, the peak splitting is obvious, the peak shape is asymmetric, and the separation effect is poor, resulting in a significant decrease in analysis accuracy and sensitivity.
[0222] 3. When the column temperature of method 3 of Example 6 is used, the spectrum obtained is not significantly improved compared with Example 1, but the higher column temperature affects the long-term use of the chromatographic column.
[0223] summary:
[0224] By adopting the preferred column temperature of the present invention, it can be achieved that except for the antisense chain impurity 5 (the impurity of incomplete thiolation sequence), the main peak and the five impurities in the obtained spectrum all have peak responses, the peak shape is sharp and the peak is smooth, and the detection sensitivity is good.
[0225] Impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolated sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), and impurity 6 (extended sequence impurity 5'n+Af) can all be separated from the main peak, with sharp and obvious peaks, no other interfering peaks, a stable baseline, and good detection sensitivity, which can realize the separation and detection of known impurities in intermediates.
[0226] On the contrary, when other column temperatures are used for separation, the characteristic peaks will overlap, have severe tailing, or the separation degree will be significantly reduced, and the separation effect cannot be achieved. Moreover, a higher column temperature does not significantly improve the separation effect, and it will also lead to a decrease in the life of the column.
[0227] Comparative Example 1:
[0228] The hydrophobic anion exchange chromatography analysis method established with reference to CN118050441A. In Comparative Example 1, the separation of the existing shortened sequence impurities (randomly removing one A / C / T / G base) and the full-length sequence (N) was investigated, but due to the poor mass spectrometry compatibility of the mobile phase, only the retention time could be used for identification, and the sequence information of the impurities could not be identified.
[0229] The comparison of the impurity types detected in Comparative Example 1 and the present invention is shown in Table 13:
[0230] Table 13
[0231]
[0232] The parameters of the hydrophobic anion exchange HPLC analysis method used in Comparative Example 1 are shown in Table 14 below. Figure 4 :
[0233] Table 14
[0234]
[0235] The blank solution, test solution, each impurity location solution and mixed impurity reference solution prepared in Example 1 were detected and separated with reference to the conditions of Comparative Example 1. The results showed that except for impurity 1 (shortened sequence impurity 5'n-1) in the sense chain and impurity 2 (incomplete thiolation impurity) in the sense chain, which can be separated from the sense chain, the remaining impurities such as impurity 3 (extended sequence impurity 5'n+Gm) in the sense chain, impurity 4 (shortened sequence impurity 5'n-1) in the antisense chain, and impurity 5 (incomplete thiolation impurity) in the antisense chain all overlapped with the sense chain or antisense chain in characteristic peaks and were not separated; therefore, the purpose of separation and detection of the sense chain, antisense chain and 6 impurities could not be achieved, and since the high concentration salt solution as the mobile phase was not compatible with the mass spectrometer, other impurities could not be identified.
[0236] Comparative Example 2:
[0237] A method for separating 12 impurities including the sense chain and antisense chain of Inclisiran (also an oligonucleotide drug targeting PCSK9), as well as shortened sequence impurities, incomplete thiolation impurities, and extended sequence impurities, was established with reference to CN116718701A using reverse ion-pair high performance liquid chromatography.
[0238] The comparison of the impurity types detected in Comparative Example 2 and the present invention is shown in Table 15:
[0239] Table 15
[0240]
[0241] The parameters of the reverse phase ion pair high performance liquid chromatography analysis method used in Comparative Example 2 are shown in Table 16 below. Figure 5 :
[0242] Table 16
[0243]
[0244] The blank solution, test solution, each impurity location solution and mixed impurity reference solution prepared in Example 1 were detected and separated with reference to the conditions of Comparative Example 2. The results showed that except for impurity 1 (shortened sequence impurity 5'n-1) and impurity 3 (lengthened sequence impurity 5'n+Gm) in the sense chain, which could be separated from the sense chain, the antisense chain was split into two peaks, and the antisense chain impurity 4 (shortened sequence impurity 5'n-1) and the sense chain impurity 3 (lengthened sequence impurity 5'n+Gm) overlapped, with obvious non-separation; therefore, the purpose of separation and detection of the sense chain, antisense chain and 6 impurities could not be achieved, and the main peak of the antisense chain was split into two peaks.
[0245] According to Example 1, the main peak and five impurities in the spectrum obtained by the method of the present invention all have peak responses, and impurity 1 (shortened sequence 5'n-1), impurity 2 (incomplete thiolated sequence impurity), impurity 3 (extended sequence impurity 5'n+Gm), impurity 4 (shortened sequence impurity 5'n-1), and impurity 6 (extended sequence impurity 5'n+Af) can be separated from the main peak, with sharp and obvious peaks, no other interfering peaks, a stable baseline, and good detection sensitivity. The separation and detection of known impurities in intermediates can be realized, and the application of the method of the present application can simultaneously realize the needs of separation and identification detection when combined with a mass spectrometer, simplifying the operation process, and providing a new way for the separation, purification and identification of oligonucleotide drugs.
Claims
1. A method for detecting impurities in an intermediate of an oligonucleotide drug targeting the PCSK9 gene, comprising using high performance liquid chromatography to separate and detect impurities in a test solution containing the oligonucleotide drug intermediate, in, The conditions for liquid chromatography include: The chromatographic column used is selected from a chromatographic column whose stationary phase uses octadecylsilane bonded silica gel as a filler; and The mobile phase A is selected from an aqueous solution of 1,1,1,3,3,3-hexafluoro-2-propanol and n-hexylamine; Mobile phase B is selected from a mixed solution of methanol and acetonitrile; Wherein, in mobile phase A, the concentration of 1,1,1,3,3,3-hexafluoro-2-propanol is 100-300 mmol / L; the concentration of n-hexylamine is 10-30 mmol / L; In mobile phase B, the volume ratio of methanol and acetonitrile was 1:1; The oligonucleotide drug comprises a sense strand and an antisense strand, the sequence of the sense strand is shown in SEQ ID NO:7, and the sequence of the antisense strand is shown in SEQ ID NO:8; The impurities include one or more of the sequence impurities of the nucleotide sequence as shown in SEQ ID NO: 1-6; The elution gradient of the liquid chromatography is: From 0 to 20 min, the volume of mobile phase B was changed from 25% to 50%; At 20-22 min, the volume of mobile phase B was changed from 50% to 60%; At 22-22.1 min, the volume of mobile phase B was changed from 60% to 25%; From 22.1 to 27 min, the volume of mobile phase B was maintained at 25%.
2. The method according to claim 1, in, The impurities are a mixture of sequence impurities such as the nucleotide sequences shown in SEQ ID NOs: 1-6.
3. The method according to claim 1, in, In mobile phase A, the concentration of 1,1,1,3,3,3-hexafluoro-2-propanol was 200 mmol / L; and / or, in mobile phase A, the concentration of n-hexylamine is 25 mmol / L; And / or, in mobile phase B, the volume ratio of methanol to acetonitrile is 1:
1.
4. The method according to claim 1, in, The particle size of the column filler is 1.7-2.7 μm; And / or, the specification of the chromatographic column is 2.1-4.6 mm×50-150 mm.
5. The method according to claim 1 or 4, in, The column packing particle size is 1.7 μm; And / or, the specification of the chromatographic column is 2.1 mm×150 mm.
6. The method according to claim 1, in, In the test solution, the concentration of the oligonucleotide drug intermediate is 0.1-1 mg / mL.
7. The method according to claim 6, in, In the test solution, the concentration of the oligonucleotide drug intermediate is 0.5-0.75 mg / mL.
8. The method according to claim 1, in, Liquid chromatography conditions also include: column temperature of 70°C; and / or, The flow rate is 0.27-0.33 mL / min; and / or, The detection wavelength is 258-262nm; and / or, The injection volume is 1-5 μL.
9. The method according to claim 8, in, The injection volume was 2 μL.
10. The method according to claim 1, in, The retention times of the oligonucleotide drug intermediates and impurities include: SEQ ID NO: 1 is 9.421 min; SEQ ID NO: 2 is 9.518 min; SEQ ID NO: 3 is 9.984 min; SEQ ID NO: 4 is 9.878 min; SEQ ID NO:5 is 11.397 min; SEQ ID NO: 6 is 11.947 min; SEQ ID NO:7 is 9.766 min; SEQ ID NO: 8 is 11.668 min; Among them, the relative deviation RD of retention time is less than 1%.
11. The method according to claim 1, in, The method further comprises the step of preparing a test solution, which comprises contacting the oligonucleotide drug with a diluent.
12. The method according to claim 11, in, The diluent is water and / or methanol.
13. The method according to claim 1, in, The method further comprises the step of using mass spectrometry to detect the purity of the product obtained by liquid chromatography.
14. The detection method according to claim 13, wherein the mass spectrometry conditions are include: The ion source is an electrospray ion source; and / or, The acquisition polarity is negative polarity mode; and / or, The acquisition range is m / z = 600-3000; and / or, The capillary voltage is 3.0KV; and / or, The drying gas temperature was 350°C.
